In short
Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in people with psoriasis, affecting joints, tendons, and ligaments in addition to skin. At CLCC, care for psoriatic arthritis follows a five-step structured assessment: Assess, Identify, Reduce, Restore, Continue, addressing the systemic contributors alongside standard medical treatment, rather than symptom management alone.
About This Condition
Psoriatic arthritis is where two autoimmune expressions, skin and joint, share one systemic upstream cascade.
Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in people with psoriasis, affecting joints, tendons, and ligaments in addition to skin. Approximately 30% of people with psoriasis develop psoriatic arthritis, typically within 10 years of skin disease onset. The pattern is highly variable: some patients have predominantly skin disease with mild joint involvement, others have severe destructive arthropathy with minimal skin changes.
The systemic drivers of PsA are the same as those of psoriasis, gut barrier dysfunction, microbiome disruption, vitamin D and zinc deficiency, systemic inflammation, and stress load, with the added structural dimension of joint involvement requiring physical rehabilitation. CLCC addresses all three dimensions simultaneously: the gut-immune environment driving both skin and joint inflammation, the nutritional deficiencies sustaining immune dysregulation, and the physical rehabilitation maintaining joint function in affected joints.
Symptoms
Common symptoms and presentations.
Joint pain, swelling, and stiffness, often asymmetric unlike RA
Psoriatic skin plaques present alongside joint symptoms
Dactylitis, 'sausage finger or toe', diffuse swelling of an entire digit
Enthesitis, pain and tenderness at tendon and ligament insertion points
Morning stiffness lasting more than 30 minutes
Nail changes, pitting, onycholysis, in most PsA patients
Back pain and stiffness from spinal involvement in some patients
Fatigue disproportionate to activity level, the systemic inflammatory burden
Contributing Factors
What drives and sustains this condition.
Gut-immune axis dysfunction
The same gut barrier disruption and microbiome alterations driving psoriatic skin disease directly fuel joint inflammation in PsA, making gut health a primary intervention target for both skin and joint outcomes.
Vitamin D and zinc deficiency
Both are essential for immune regulation and skin barrier function. Therapeutic correction helps improve both skin and joint disease activity in PsA.
Systemic inflammation
Elevated TNF-alpha, IL-17, and IL-23, the cytokines targeted by PsA biologicals, are sustained by the same gut, dietary, and stress factors as in psoriasis. Addressing these reduces the baseline cytokine environment.
Structural and biomechanical factors
Joint involvement in PsA produces progressive structural damage if inadequately managed. Physical rehabilitation addresses joint stability, mobility, and entheseal health alongside the systemic immune correction.
The CLCC Method: All Five Steps
Assessment first. Then all five steps, applied specifically.
Assess gut health, nutritional status, inflammatory markers, and physical function together
Gut barrier integrity, microbiome indicators, vitamin D, zinc, inflammatory markers, and joint function assessed comprehensively, skin and joint disease evaluated as expressions of the same systemic cascade.
Identify the dominant driver, gut, nutritional, stress, or metabolic, and severity of joint involvement
The balance between skin and joint disease, and the severity of structural involvement, determines care plan priority, whether gut restoration or structural rehabilitation receives initial emphasis.
Coordinated gut, nutritional, anti-inflammatory, and physical rehabilitation
Gut barrier repair and microbiome restoration. Therapeutic vitamin D3 and zinc. Anti-inflammatory dietary protocol. Physical rehabilitation staged for PsA joint pattern, entheseal protection, joint mobility, and progressive strengthening in parallel.
Track both skin and joint disease activity alongside systemic markers
PASI for skin and joint functional scoring tracked together at defined intervals. Nutritional markers reviewed. Protocol refined based on the relative response of skin and joint dimensions.
Long-term management of both skin and joint health
PsA is a lifelong condition requiring sustained monitoring. The Continue phase maintains the immune environment, nutritional status, and physical function gains, preventing structural progression and managing the fluctuating nature of PsA activity.
FAQs
Common questions about care.
Is PsA managed differently from psoriasis alone?+
PsA requires the addition of structural rehabilitation alongside the systemic gut and immune correction used for psoriasis. The systemic approach is similar, gut health, vitamin D, zinc, anti-inflammatory nutrition, but the physical dimension of joint management is mandatory and specific to PsA.
Does improving my psoriasis help my joints?+
The same systemic drivers, gut dysfunction, vitamin D deficiency, inflammatory load, affect both skin and joint disease. Improvements in the systemic inflammatory environment tend to benefit both simultaneously, even when they appear to be separate problems.